CJC-1295 (without DAC)

What is CJC-1295 (without DAC)?

CJC-1295 (without DAC) is a synthetic ghrh analog (mod grf 1-29).

CJC-1295 without DAC, also called Modified GRF 1-29, or Mod GRF 1-29, is a lab-made version of growth hormone releasing hormone (GHRH), the body's own signal for releasing growth hormone. This short-acting form prompts growth hormone to come out in bursts, much like the body's natural pattern. Its half-life is only about 30 minutes, far shorter than the DAC-modified version. Researchers note that the short window allows finer control over each growth hormone pulse and lowers the chance that the receptor stops responding.

Key research areas

• Preserves natural GH pulsatility
• Minimal side effects
• No receptor desensitization
• Precise control over GH release

Researched dosing

This table reflects how researchers structure study designs with CJC-1295, the dose ranges and schedules used in published research, presented as methodology reference, not usage instructions.

Commonly cycled 16 weeks on, 4+ weeks off.

How it works

At the cell level, CJC-1295 research looks at how the peptide binds GHRH receptors on the pituitary gland, prompting a burst of growth-hormone release similar to the body's own signaling pattern.

Binds to GHRH receptors on somatotroph cells, stimulating cAMP production and triggering growth hormone release in physiological pulses

Molecular data

These figures, molecular weight, amino-acid sequence, chain length, are the chemistry basics researchers use to confirm a CJC-1295 sample's identity and purity.

Weight

3367.97 Da

Length

30 amino acids

Type

GHRH analog (Mod GRF 1-29)

Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys

Pharmacokinetics

This chart shows how quickly a research dose of CJC-1295 clears the body, notice the timescale is minutes, not days, which is why this version is studied for short, pulsatile GH release rather than sustained elevation.

What the studies report

This section lists the research areas scientists have studied for CJC-1295, a summary of what's been investigated in the literature, not medical claims about people.

Dosage reference

Doses used in research

100 mcg per research dose (10 units at the common 100 mcg / 10 unit mixing ratio)

Frequency in studies

2-3 times daily for pulsatile release

Handling

Reconstituted solution, research use only; not for administration

Timeline reported in studies

GH elevation within 30 minutes, IGF-1 increases in 2-4 weeks, body composition changes in 6-12 weeks

Storage

Refrigerate immediately, use within 30 days of reconstitution

Cycle length

12-16 weeks continuous use

Break between cycles

Optional 2-4 week breaks to assess baseline

Interactions

This list shows which other growth-hormone-research peptides are studied alongside CJC-1295, and why they're often paired in published protocols.

Reconstitution & storage

This is the standard laboratory method for turning freeze-dried CJC-1295 powder into a liquid research solution.

1. Allow vial to reach room temperature (15-20 minutes)
2. Clean vial top with alcohol swab and allow to dry
3. Calculate required bacteriostatic water volume using the calculator below
4. Draw calculated volume of bacteriostatic water into syringe
5. Inject water slowly down the inside wall of the vial (never directly onto powder)
6. Gently swirl until powder completely dissolves (never shake)
7. Solution should be clear - discard if cloudy or contains particles

Lyophilized: Room temperature, stable for 2 years if stored properly, use within 2 years

Reconstituted: 2-8°C, use within 30 days

Quality indicators

These are the checks researchers and lab-report reviewers use to confirm a CJC-1295 sample is pure and correctly identified before it goes into a study.

What to expect

This timeline summarizes what the research literature reports at each study stage, research context for comparing studies, not a personal-results promise.

Regulatory status

• Not approved by the FDA for any indication.
• Supplied and described for laboratory research use only, not for human or veterinary use.

What is not known

The limits of the published work on CJC-1295 (without DAC), stated plainly. Research use only: none of this is guidance for a person.

The published human trials tested the long acting DAC version, the one that sticks to a blood protein and lasts about eight days. This entry is about the short acting form without DAC, and no trial of that form has been published, so what it does in a person is not known.

So the roughly thirty minute half life quoted for the form without DAC does not come from a published human trial. It is read off the chemistry and off smaller reports.

The trials measured hormone levels in the blood. They did not measure whether anything else changed, so they cannot say what releasing growth hormone in bursts is worth.

What long use of the form without DAC does is not known, because no such study has been run.

The idea that keeping the natural burst pattern avoids the receptor going quiet is a reason for the design, not a finding. There is no evidence that it happens with this form.

The terms, in plain words

Every technical term this page leans on, said again in ordinary words.

GHRH

The natural signal a body makes to tell the pituitary gland it is time to let growth hormone out.

DAC

Drug affinity complex, a chemical tag that sticks the peptide to a protein in the blood so it lasts days instead of minutes.

Pulsatile

Released in bursts rather than as a steady drip.

Half life

The time it takes for half of a dose to clear the body.

Somatotroph

The pituitary cell that makes growth hormone.

Desensitisation

When a receptor stops answering a signal it has been getting constantly.

Sources

The published work behind this entry. Each link was opened and each note says what that paper reports, not what it suggests.

1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology and Metabolism, 2006Healthy adults. Two placebo controlled rising dose trials of the long acting DAC version, not of the short acting form this entry describes.
2. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog Journal of Clinical Endocrinology and Metabolism, 2006Healthy adults. Reports that growth hormone still came out in bursts while the long acting DAC version was working. Again, the DAC version.

How it is studied

In the published studies listed below. Each one names the species it was run in, the dose, how long it ran, and what it reported.

How it compares with related peptides

These entries sit closest to CJC-1295 (without DAC). Each card names the peptide's category, what it is studied for, and how much research exists, so the differences are readable side by side.